| 1. | | Not yet recruiting | Acupuncture for Women's Health Conditions
Conditions: Ovarian Neoplasms; Endometriosis; Pelvic Pain; Uterine Neoplasms |
| 2. | | Recruiting | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
Conditions: Breast Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Lung Neoplasms |
| 3. | | Recruiting | Tariquidar and Docetaxel to Treat Patients with Lung, Ovarian, and Cervical Cancer
Conditions: Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms |
| 4. | | Recruiting | TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms |
| 5. | | Recruiting | Pilot Study of ZD1839 (Iressa, Gefitinib) in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, or Cervical Cancer
Conditions: Ovarian Neoplasms; Cervix Neoplasms |
| 6. | | Recruiting | Removal of the ovaries/fallopian tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Conditions: Ovarian Neoplasms; Breast Neoplasms |
| 7. | | Recruiting | Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Conditions: Breast Neoplasms; Ovarian Neoplasms |
| 8. | | Recruiting | Phase II Trial of Gleevec in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Neoplasms; Pelvic Neoplasms; Peritoneal Neoplasms |
| 9. | | Recruiting | Tandem cycles of high dose chemotherapy followed by stem cell support for ovarian cancer
Condition: Ovarian Neoplasms |
| 10. | | Recruiting | Experimental Drug SS1(dsFv)-PE38 to Treat Cancer
Conditions: Mesothelioma; Ovarian Neoplasm; Squamous Cell Neoplasm |
| 11. | | Recruiting | A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)
Condition: Ovarian Neoplasm |
| 12. | | Recruiting | Microarray Analysis for Human Genetic Disease
Conditions: Breast Neoplasm; Hereditary Neoplastic Syndrome; Melanoma; Ovarian Neoplasm |
| 13. | | Recruiting | p53 Vaccine for Ovarian Cancer
Condition: Ovarian Neoplasm |
| 14. | | Not yet recruiting | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
| 15. | | Recruiting | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Treating Patients With Recurrent Late-Stage Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer |
| 16. | | Recruiting | Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: stage I ovarian epithelial cancer; stage II ovarian epithelial cancer; stage III ovarian epithelial cancer; peritoneal cavity cancer |
| 17. | | Recruiting | FR901228 in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
| 18. | | Recruiting | Second-Line Treatment for Patients with Platinum-Sensitive Ovarian Cancer
Condition: Ovarian Cancer |
| 19. | | Recruiting | Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
| 20. | | Recruiting | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
| 21. | | Recruiting | Study of Ovarex® (oregovomab) MAb with Front-line Chemotherapy for Ovarian Cancer Treatment
Condition: Ovarian Cancer |
| 22. | | Not yet recruiting | FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
| 23. | | Recruiting | PEG-Interferon alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer |
| 24. | | Recruiting | Carboplatin Plus Docetaxel and Paclitaxel in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
| 25. | | Recruiting | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer |
| 26. | | Recruiting | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma |
| 27. | | Recruiting | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
| 28. | | Not yet recruiting | A Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Condition: Ovarian Cancer |
| 29. | | Not yet recruiting | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
| 30. | | Recruiting | CA-125 in Screening Patients at High Risk for Ovarian Cancer
Condition: ovarian epithelial cancer |
| 31. | | Recruiting | Adjuvant Intraperitoneal Carboplatin With Paclitaxel in Treating Patients Who Had Initial Debulking Surgery for Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
| 32. | | Recruiting | TLK286 Compared With Either Liposomal Doxorubicin or Topotecan as Third-Line Therapy in Treating Patients With Platinum-Refractory or Platinum-Resistant Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
| 33. | | Recruiting | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
Conditions: adult solid tumor; Breast Cancer; Lung Cancer; neurotoxicity; ovarian epithelial cancer; Prostate Cancer |
| 34. | | Recruiting | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer |
| 35. | | Recruiting | Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
| 36. | | Recruiting | Oral Tyrosine Kinase Inhibitor of VEGFR-2 to Treat Recurrent or Persistent Small-volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer
Condition: Ovarian Cancer |
| 37. | | Recruiting | A study of the safety and effects of EMD 72000 in subjects with recurrent ovarian cancer
Condition: Ovarian Cancer |
| 38. | | Recruiting | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
| 39. | | Recruiting | Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer |
| 40. | | Recruiting | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; ... |
| 41. | | Recruiting | Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
Conditions: adult brain tumor; extragonadal germ cell tumor; ovarian germ cell tumor; Testicular Cancer |
| 42. | | Recruiting | Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Conditions: stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer |
| 43. | | Recruiting | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: stage II ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer; ... |
| 44. | | Recruiting | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; stage III ovarian epithelial cancer; ... |
| 45. | | Recruiting | Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Conditions: Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms |
| 46. | | Recruiting | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
| 47. | | Recruiting | Combination Chemotherapy Plus Erlotinib in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer |
| 48. | | Recruiting | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
| 49. | | Not yet recruiting | CA 125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women
Condition: ovarian epithelial cancer |
| 50. | | Recruiting | Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; Fallopian Tube Cancer; peritoneal cavity cancer |
